Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Technical Note

Potential impact of SARS COV-2 infection on the performance of serological assays used to diagnose arboviral diseases

Dhanalakshmi Gounassegarane a, Anitha Gunalan a, Imola Jamir a, Ferdina Marie Sharmila b, Rajamani Barathidasan b, Ratchagadasse Vimal Raj b, Rahul Dhodapkar a, *

a Department of Microbiology, JIPMER, Puducherry, India
b Regional Viral Research and Diagnostic Laboratory (RVRDL), Department of Microbiology, JIPMER, Puducherry, India

ARTICLE INFO

Keywords:
SARS CoV-2
Arboviruses
Cross reaction
Dengue
Chikungunya

ABSTRACT

Background: The COVID-19 pandemic caused by SARS-CoV-2 was first described in December 2019, in China. In addition, there has also been an increase in arboviral infections in recent years. As both infections have similar symptoms, misdiagnosis may occur if both outbreaks occur at the same time.

Objective: Our objective was to assess the potential impact of SARS-CoV-2 infection on diagnostic assays used for arboviral diseases.

Materials and methods: We conducted this study by testing samples obtained during the precovid phase (before November 2019) and during the covid period (after February 2020). Samples were further grouped as those with acute febrile illness (AFI) and those without. All samples were tested for anti SARS-CoV-2 Ab, Chikungunya and Dengue specific IgM antibodies to evaluate potential serological cross-reactions between COVID-19 and Arbovirus specific antibodies.

Results: One sample from the 62 cases of AFI during the pre-covid phase showed seropositivity for SARS-CoV-2 antibodies. Also, in asymptomatic individuals, arboviral seropositivity was significantly higher in the COVID period samples (22%) compared to pre-COVID samples (3%).

Conclusion: Due to similar clinical symptoms and cross reactions in both infections, relying solely on serological testing for arboviral diagnosis may be less sensitive; other clinical and laboratory parameters may be required.

1. Introduction

The Coronavirus disease (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from Wuhan, capital of Hubei Province, China in December 2019 and has spread worldwide. On March 11, 2020 COVID-19 was declared a pandemic by the World Health Organization. Upto December 2021, almost 281 million cases had been reported with 5 million deaths (World Health Organization, 2021). The COVID-19 pandemic has triggered a global economic crisis on a scale never seen before. The common symptoms of patients infected with SARS-CoV-2 includes fever, headache, loss of taste and smell, cough and sore throat. These symptoms vary from mild, moderate to severe in different groups of people which creates a diagnostic dilemma overloading the healthcare facilities (Baloch et al., 2020). The coexistence of COVID-19 and other viral infections has been a source of concern, especially for countries located in the tropical and subtropical regions where there is a higher prevalence of arboviral diseases (United Nations Department of Economic and Social Affairs (UN DESA), 2021; Liang et al., 2015). The co-circulation of arboviruses such as Dengue and Chikungunya, which are not completely understood, adds to the health-care burden. These arboviral infections usually presents as fever, headache, retro-orbital pain, musculoskeletal pain and transient rash (Lorenz et al., 2020; Saavedra-Velasco et al., 2020). Though there are some clinical signs and symptoms which may be indicative of COVID-19 and dengue infection, still there is a constant warning by the epidemiologists all over the world regarding the temporal coincidence relating to the COVID-19 and arboviruses (especially dengue) as both share similar clinical features and laboratory findings leading to diagnostic and management challenges (Lorenz et al., 2020; Saavedra-Velasco et al., 2020; Yan et al., 2020). Therefore in the present study we aimed to assess the potential impact of SARS-CoV-2 infection on diagnostic assay used for the diagnosis of arboviral diseases.

* Corresponding author at: Department of Microbiology, JIPMER, Puducherry 605009, India.
E-mail address: rahuldhodapkar@gmail.com (R. Dhodapkar).

https://doi.org/10.1016/j.jim.2022.113312
Received 26 February 2022; Received in revised form 27 June 2022; Accepted 28 June 2022
Available online 4 July 2022
0022-1759/© 2022 Elsevier B.V. All rights reserved.
2. Methodology

2.1. Patient cohort

In our study, we tested samples obtained during different time periods, during the precovid phase (August 2019–November 2019) and also during the covid pandemic (July 2020–March 2021). We investigated potential serological cross-reactions between COVID-19 and Arbovirus (Dengue and chikungunya virus) specific antibodies by performing commercial assays on sera obtained from well-characterized COVID-19 and arbovirus infected patients with demonstrated seropositivity. For our study convenience we have divided the samples into different groups. In the pre-covid phase, samples were categorized as those collected from patients without febrile illness (P1) and those with febrile illness patients (P2). During covid phase, samples from patients without febrile illness (C1) were grouped. From precovid phase, 50 samples were chosen in random from asymptomatic individuals (P1), 62 samples from patients with febrile illness (P2), 3 samples were serologically equivocal for arbovirus antibodies, as listed in Table 1. In our study, when we examined the pre-COVID samples, the set of samples from asymptomatic individuals (P1) did not show any seropositivity for SARS-CoV-2. However, from the pre-COVID samples drawn from cases of acute febrile illness (P2), one sample (1/62) showed seropositivity for SARS-CoV-2. In the asymptomatic pre-COVID samples (P1), 3 samples showed seropositivity to arbovirus; whereas during the COVID period, from samples of asymptomatic individuals who had serologic evidence of SARS-CoV-2 infection (C1), arboviral seropositivity was observed in 22% of samples. The seropositivity in P1 can be explained by prolonged IgM positivity or asymptomatic arboviral presentation, however in C1 this proportion is higher than expected.

2.2. Serological testing

All the above said samples collected during both pre-covid and covid phase were tested for the presence of anti SARS-CoV-2 total Ab (Wantai SARS CoV2 Ab ELISA kit), Chikungunya specific IgM antibodies (National Institute of Virology Chikungunya IgM capture ELISA kit) and Dengue specific IgM antibodies (National Institute of Virology Dengue IgM capture ELISA kit).

3. Results

In P1 group, all 50 samples tested were serologically negative for anti-SARS CoV-2 total antibodies. Three samples were seropositive and 10 were serologically equivocal for arbovirus antibodies, as listed in Table 1.

In P2, out of the 62 samples, only one sample was seropositive for both dengue and SARS CoV-2 as depicted in Table 2.

In C1, 50 of the anti SARS-CoV-2 antibody seropositive samples were tested for arbovirus antibodies, of which 11 were seropositive and 14 were serologically equivocal (see Table 3). There is significant increase in Dengue rates (p value = 0.027) in C1 group as compared with rates detected in P1 group by chi square test.

4. Discussion

An additional strain has been put on health care systems by the ongoing SARS CoV-2 pandemic and the situation becomes more complicated in arboviruses endemic areas. At present, in addition to the SARS CoV-2 cases observed, arboviral infections continue to spread mainly in the tropical areas (Cattarino et al., 2020). Arboviral infections, dengue and Chikungunya, share similar clinical manifestations as are commonly observed with the SARS CoV-2 infected patients, which poses a diagnostic dilemma (Di Gennaro et al., 2020; Nacher et al., 2020). The primary diagnostic modality for SARS-CoV-2 infection is RT-PCR or antigen detection test from throat/nasal swab, whereas arboviral disease diagnosis primarily depends on serologic detection of antigen or antibodies in serum.

In our study, when we examined the pre-COVID samples, the set of samples from asymptomatic individuals (P1) did not show any seropositivity for SARS-CoV-2. However, from the pre-COVID samples drawn from cases of acute febrile illness (P2), one sample (1/62) showed seropositivity for SARS-CoV-2. In the asymptomatic pre-COVID samples (P1), 3 samples showed seropositivity to arbovirus; whereas during the COVID period, from samples of asymptomatic individuals who had serologic evidence of SARS-CoV-2 infection (C1), arboviral seropositivity was observed in 22% of samples. The seropositivity in P1 can be explained by prolonged IgM positivity or asymptomatic arboviral presentation, however in C1 this proportion is higher than expected.

Lustig Y et al. in their study (March 17, 2020–April 13, 2019) observed simultaneous seropositivity for SARS CoV2 and Dengue, they attributed it to structural similarity, however in the current study our set of samples which were positive for arboviral serology from pre-covid period (P2), we observed SARS CoV2 seropositivity in only one case (n = 62) (Lustig et al., 2021).

In a study conducted by Stringari LL et al., it was observed that from a total of 7730 patients who were suspected with dengue and chikungunya, 210 were seropositive for anti-SARS-CoV-2 IgG (Stringari et al., 2021).

Although IgM/IgG-detecting serological assays are used to diagnose arboviral infections, they cannot be used to diagnose SARS-CoV-2.

SARS-CoV-2 can cause immune system hyper-stimulation. It is linked to changes in circulating leukocytes and a significant increase in pro-inflammatory cytokines such as interleukins (IL-6, IL-1), and Tumor necrosis factor (TNF-a), which can in some instances cause a “cytokine storm” in patients (Dotan et al., 2021). In addition to the virus's propensity to cause immune system hyper-stimulation, current research has shown a main sequence homology between humans and SARS-CoV-2 components. Antibodies produced by this acquired immune system cross-react with common molecules present in pathogens and self-components. Increased seropositivity for arboviral infections may be due to this altered immune response seen in SARS-CoV-2 infection (Dotan et al., 2021).

As a result, complete reliance on serological tests for arboviral diagnosis may be misleading due to similar clinical manifestations and cross reaction in both infections. It may be advisable to use other clinical and laboratory parameters to arrive at clinical diagnosis.
There are two main limitations of this study—first, diagnosis of dengue and chikungunya was based on IgM whereas SARS-CoV-2 sero-positivity was based on total Ig.

Second, PRNT (plaque reduction neutralisation test) could not be performed to verify arboviral diagnosis.

Data availability

No data was used for the research described in the article.

References

Baloch, S., Baloch, M.A., Zheng, T., Pei, X., 2020. The coronavirus disease 2019 (COVID-19) pandemic. Tobu J. Exp. Med. 250, 271–278.
Cattarino, L., Rodríguez-Barraquer, I., Imai, N., Cummings, D.A.T., Ferguson, N.M., 2020. Mapping global variation in dengue transmission intensity. Sci. Transl. Med. 12, 1–11.
Chelluboina, S., Robin, S., Aswathyraj, S., Arunkumar, G., 2019. Persistence of antibody response in chikungunya. Virusdisease. 30 (3), 469–473. Sep.
Di Gennaro, F., Marotta, C., Locantore, P., Pizzol, D., Putoto, G., 2020. Malaria and COVID-19: common and different findings. Trop. Med. Infect. Dis. 5 (3), 141. Sep 6.
Dotan, A., Muller, S., Kanduc, D., David, P., Halpert, G., Shoenfeld, Y., 2021. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 20 (4). Apr. (102792).
D. Gounassegarane et al.

Liang, G., Gao, X., Gould, E.A., 2015. Factors responsible for the emergence of arboviruses; strategies, challenges and limitations for their control. Emerg. Microbes Infect. 4 (3), e140.
Lorenz, C., Azevedo, T.S., Chiaraavalloti-Neto, F., 2020. COVID-19 and dengue fever: a dangerous combination for the health system in Brazil. Travel Med. Infect. Dis. 35, 101659.
Lustig, Y., Keler, S., Kolodny, R., Ben-Tal, N., Atlas-Varon, D., et al., 2021. Potential antigenic cross-reactivity between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and dengue viruses. Clin. Infect. Dis. 73 (7), e2444–e2449. Oct 1.
Nacher, M., Dousse, M., Gaillet, M., Flamand, C., Rouset, D., Rousseau, C., et al., 2020. Simultaneous dengue and COVID-19 epidemics: difficult days ahead? PLoS Negl. Trop. Dis. 14 (8), e0008426.
Saavedra-Velasco, M., Chiara-Chilet, C., Pichardo-Rodriguez, R., Grandez-Urbina, A., Inga-Berrospi, F., 2020. Coinfection between dengue and covid-19: need for approach in endemic zones. Rev. Fac. Cienc. Medicas Cordoba Argent. 77, 52–54. https://doi.org/10.31053/1853.0605.v77.n1.28031.
Stringari, L.L., de Souza, M.N., de Medeiros Junior, N.F., Goulart, J.P., Giuberti, C., et al., 2021. Covert cases of severe acute respiratory syndrome coronavirus 2: an obscure but present danger in regions endemic for dengue and chikungunya viruses. PLoS One 16 (1). Jan 6. (e0244937).
United Nations Department of Economic and Social Affairs (UN DESA), 2021. World Economic Situation & Prospects: Report 12; United Nations: New York, NY, USA (ISBN 978-92-1-005486-0).
World Health Organization, 2021. WHO Coronavirus Disease (COVID-19) Dashboard. WHO, Geneva. Available from. https://covid19.who.int.
Yan, G., Lee, C.K., Lam, I.T.M., Yan, B., Chua, Y.X., Lim, A.Y.N., et al., 2020. Covert COVID-19 and false-positive dengue serology in Singapore. Lancet Infect. Dis. 20 (5), 536.